



Endorsement of International Consensus Radiochemistry Nomenclature Guidelines

Philip Elsinga¹ · Angelika Bischof Delaloye² · Arturo Chiti^{3,4} · Stefaan Vandenberghe⁵ · Francesco Giammarile⁶ · Ignasi Carrio⁷

Received: 8 November 2018 / Accepted: 8 November 2018 / Published online: 16 April 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

With the open letter published in *EJNMMI Radiopharmacy and Chemistry* by an international working group of experts, the EJNMMI journal family endorses the application of the guidelines in contributions to the journals.

Attached to the letter by the working group is a three-page summary highlighting the most relevant issues in the notation of radiopharmaceuticals and related terms.

The full paper with all recommendations is published in the article “Consensus nomenclature rules for radiopharmaceutical chemistry—setting the record straight Coenen, H.H., Gee A.D. et al., *Nuclear Medicine and Biology*, Vol. 55, pages v–xi (2017) (<https://doi.org/10.1016/j.nucmedbio.2017.09.004>).”

All editors-in chief of the EJNMMI journals strongly recommend that all manuscripts meet these guidelines upon submission. In addition, all reviewers will be asked to be aware of the guidelines and, wherever possible, to check whether the guidelines are followed.

Editors-in-Chief,
Philip Elsinga
Angelika Bischof Delaloye
Arturo Chiti
Stefaan Vandenberghe
Francesco Giammarile
Ignasi Carrio

Compliance with ethical standards

Competing interests The authors declare that they have no competing interests.

Authors' contributions All authors read and approved the final manuscript.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is co-published in the *European Journal of Nuclear Medicine and Molecular Imaging*, *EJNMMI Research*, *EJNMMI Physics*, *EJNMMI Radiopharmacy and Chemistry*, and *European Journal of Hybrid Imaging*, and is available at <https://doi.org/10.1186/s41181-018-0050-3>, <https://doi.org/10.1007/s00259-018-4243-5>, <https://doi.org/10.1186/s13550-018-0469-2>, <https://doi.org/10.1186/s40658-018-0237-4> and <https://doi.org/10.1186/s41824-018-0048-9> respectively.

✉ Philip Elsinga
p.h.elsinga@umcg.nl

¹ Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ Groningen, The Netherlands

² Nuclear Medicine Service, Centre Hospitalier Universitaire Vaudois, Bugnon 46, 1011 Lausanne, Switzerland

³ Department of Biomedical Sciences, Humanitas University, Milan, Italy

⁴ Department of Diagnostic Imaging, Humanitas Clinical and Research Center – IRCCS, Milan, Italy

⁵ MEDISIP-ELIS-IBITECH, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium

⁶ Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria

⁷ Department of Radiology and Medical Physics, Hospital de Sant Pau, Barcelona, Spain